Is 4D Molecular Stock a Good Investment?
4D Molecular Investment Advice | FDMT |
- Examine 4D Molecular's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research 4D Molecular's leadership team and their track record. Good management can help 4D Molecular navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact 4D Molecular's business and its evolving consumer preferences.
- Compare 4D Molecular's performance and market position to its competitors. Analyze how 4D Molecular is positioned in terms of product offerings, innovation, and market share.
- Check if 4D Molecular pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about 4D Molecular's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in 4D Molecular Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if 4D Molecular Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine 4D Molecular Stock
Researching 4D Molecular's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 96.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.67. Some equities with similar Price to Book (P/B) outperform the market in the long run. 4D Molecular Therapeutics recorded a loss per share of 2.85. The entity had not issued any dividends in recent years.
To determine if 4D Molecular is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding 4D Molecular's research are outlined below:
| 4D Molecular generated a negative expected return over the last 90 days | |
| 4D Molecular has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 20.72 M. Net Loss for the year was (100.84 M) with loss before overhead, payroll, taxes, and interest of (77.12 M). | |
| 4D Molecular Therapeutics currently holds about 241.09 M in cash with (75.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.45. | |
| 4D Molecular has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: Disposition of 500 shares by Bizily Scott of 4D Molecular at 6.49 subject to Rule 16b-3 |
4D Molecular Quarterly Accounts Payable |
|
4D Molecular uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in 4D Molecular Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to 4D Molecular's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact 4D Molecular's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises 4D Molecular's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-08 | 2024-06-30 | -0.7 | -0.63 | 0.07 | 10 | ||
2024-05-09 | 2024-03-31 | -0.74 | -0.66 | 0.08 | 10 | ||
2024-11-07 | 2024-09-30 | -0.7 | -0.79 | -0.09 | 12 | ||
2022-11-08 | 2022-09-30 | -0.91 | -0.79 | 0.12 | 13 | ||
2023-11-09 | 2023-09-30 | -0.59 | -0.24 | 0.35 | 59 | ||
2021-08-12 | 2021-06-30 | -0.68 | -0.28 | 0.4 | 58 | ||
2021-05-13 | 2021-03-31 | -1.1 | -0.61 | 0.49 | 44 | ||
2021-03-25 | 2020-12-31 | -0.66 | -2.36 | -1.7 | 257 |
Know 4D Molecular's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as 4D Molecular is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading 4D Molecular Therapeutics backward and forwards among themselves. 4D Molecular's institutional investor refers to the entity that pools money to purchase 4D Molecular's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Polar Capital Holdings Plc | 2024-06-30 | 1.7 M | Assenagon Asset Management Sa | 2024-09-30 | 1.5 M | Novo A/s | 2024-09-30 | 1.5 M | Redmile Group, Llc | 2024-09-30 | 1.3 M | Braidwell Lp | 2024-09-30 | 1.2 M | Casdin Capital, Llc | 2024-09-30 | 1.1 M | Geode Capital Management, Llc | 2024-06-30 | 1.1 M | Eventide Asset Management, Llc | 2024-06-30 | 881.2 K | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-06-30 | 850.2 K | Bvf Inc | 2024-09-30 | 7.4 M | Ra Capital Management, Llc | 2024-06-30 | 5.1 M |
4D Molecular's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 369.36 M.Market Cap |
|
4D Molecular's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.33) | (0.31) |
Determining 4D Molecular's profitability involves analyzing its financial statements and using various financial metrics to determine if 4D Molecular is a good buy. For example, gross profit margin measures 4D Molecular's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of 4D Molecular's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in 4D Molecular's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of 4D Molecular Therapeutics. Check 4D Molecular's Beneish M Score to see the likelihood of 4D Molecular's management manipulating its earnings.
Evaluate 4D Molecular's management efficiency
4D Molecular Therapeutics has return on total asset (ROA) of (0.1686) % which means that it has lost $0.1686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2406) %, meaning that it created substantial loss on money invested by shareholders. 4D Molecular's management efficiency ratios could be used to measure how well 4D Molecular manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.31 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, 4D Molecular's Liabilities And Stockholders Equity is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 800.4 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 14.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.87 | 8.26 | |
| Tangible Book Value Per Share | 7.87 | 8.26 | |
| Enterprise Value Over EBITDA | (5.21) | (5.47) | |
| Price Book Value Ratio | 2.58 | 2.70 | |
| Enterprise Value Multiple | (5.21) | (5.47) | |
| Price Fair Value | 2.58 | 2.70 | |
| Enterprise Value | 558.3 M | 587.6 M |
4D Molecular Therapeutics has shown resilience through effective management strategies. Our analysis examines how these strategies influence financial outcomes and investor returns which helps in understanding the stock's long-term potential.
Beta 2.804 |
Basic technical analysis of FDMT Stock
As of the 23rd of November, 4D Molecular owns the Information Ratio of (0.24), market risk adjusted performance of 3.72, and Variance of 17.35. 4D Molecular Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.4D Molecular's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific 4D Molecular insiders, such as employees or executives, is commonly permitted as long as it does not rely on 4D Molecular's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases 4D Molecular insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
4D Molecular's Outstanding Corporate Bonds
4D Molecular issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. 4D Molecular Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most FDMT bonds can be classified according to their maturity, which is the date when 4D Molecular Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View |
Understand 4D Molecular's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing 4D Molecular's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | 3.72 | |||
| Mean Deviation | 2.82 | |||
| Coefficient Of Variation | (473.96) | |||
| Standard Deviation | 4.17 | |||
| Variance | 17.35 | |||
| Information Ratio | (0.24) | |||
| Jensen Alpha | (0.87) | |||
| Total Risk Alpha | (1.43) | |||
| Treynor Ratio | 3.71 | |||
| Maximum Drawdown | 25.71 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 5.15 | |||
| Skewness | (1.25) | |||
| Kurtosis | 6.3 |
| Risk Adjusted Performance | (0.15) | |||
| Market Risk Adjusted Performance | 3.72 | |||
| Mean Deviation | 2.82 | |||
| Coefficient Of Variation | (473.96) | |||
| Standard Deviation | 4.17 | |||
| Variance | 17.35 | |||
| Information Ratio | (0.24) | |||
| Jensen Alpha | (0.87) | |||
| Total Risk Alpha | (1.43) | |||
| Treynor Ratio | 3.71 | |||
| Maximum Drawdown | 25.71 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 5.15 | |||
| Skewness | (1.25) | |||
| Kurtosis | 6.3 |
Consider 4D Molecular's intraday indicators
4D Molecular intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of 4D Molecular stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 63252.33 | |||
| Daily Balance Of Power | (0.34) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 7.82 | |||
| Day Typical Price | 7.81 | |||
| Price Action Indicator | (0.13) | |||
| Period Momentum Indicator | (0.20) |
4D Molecular Corporate Filings
13A | 15th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 6th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 18th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of August 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
FDMT Stock media impact
Far too much social signal, news, headlines, and media speculation about 4D Molecular that are available to investors today. That information is available publicly through FDMT media outlets and privately through word of mouth or via FDMT internal channels. However, regardless of the origin, that massive amount of FDMT data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of 4D Molecular news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of 4D Molecular relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to 4D Molecular's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive 4D Molecular alpha.
4D Molecular Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards 4D Molecular can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
4D Molecular Corporate Management
| FAAAAI FAAP | Senior Pulmonology | Profile | |
| Uneek Mehra | Chief Officer | Profile | |
| JD Esq | Chief Officer | Profile | |
| Mike Zanoni | VP Relations | Profile | |
| Noriyuki MD | Chief Officer | Profile | |
| Karen Carothers | Controller | Profile |
Additional Tools for FDMT Stock Analysis
When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.